GTHX

GTHX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
GTHX Income Statement
GTHX Balance Sheet
GTHX Cash Flow
Congress Trading

Recent trades of GTHX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
GTHX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
GTHX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
GTHX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by GTHX's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Transient protection of normal cells during chemotherapy Aug. 08, 2023
  • Patent Title: Synthesis of 1,4-diazaspiro[5.5]undecan-3-one Jul. 25, 2023
  • Patent Title: Hspc-sparing treatments for rb-positive abnormal cellular proliferation May. 23, 2023
  • Patent Title: Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors May. 09, 2023
  • Patent Title: Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines Apr. 18, 2023
  • Patent Title: Preservation of immune response during chemotherapy regimens Dec. 20, 2022
  • Patent Title: Anti-neoplastic combinations and dosing regimens using cdk4/6 inhibitor compounds to treat rb-positive tumors Sep. 20, 2022
  • Patent Title: Treatment of egfr-driven cancer with fewer side effects Jul. 26, 2022
  • Patent Title: Combination therapy for treatment of cancer Jun. 21, 2022
  • Patent Title: G1t38 superior dosage regimes Jun. 14, 2022
  • Patent Title: Transient protection of normal cells during chemotherapy Jun. 22, 2021
  • Patent Title: Morphic forms of trilaciclib and methods of manufacture thereof Apr. 27, 2021
  • Patent Title: Benzothiophene estrogen receptor modulators Apr. 20, 2021
  • Patent Title: Transient protection of normal cells during chemotherapy Apr. 06, 2021
  • Patent Title: Hspc-sparing treatments for rb-positive abnormal cellular proliferation Feb. 23, 2021
  • Patent Title: Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines Dec. 15, 2020
  • Patent Title: Highly active anti-neoplastic and anti-proliferative agents Jul. 14, 2020
  • Patent Title: Cdk inhibitors Jun. 30, 2020
  • Patent Title: Antiproliferative pyrimidine-based compounds May. 19, 2020
  • Patent Title: Hspc-sparing treatments for rb-positive abnormal cellular proliferation Oct. 08, 2019
  • Patent Title: Treatment of rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors Sep. 17, 2019
  • Patent Title: Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation Aug. 13, 2019
  • Patent Title: Benzothiophene estrogen receptor modulators Feb. 19, 2019
  • Patent Title: Cdk inhibitors Jan. 29, 2019
  • Patent Title: Cdk inhibitors Jan. 29, 2019
  • Patent Title: Cdk inhibitors Jan. 29, 2019
  • Patent Title: Transient protection of normal cells during chemotherapy Oct. 02, 2018
  • Patent Title: Hspc-sparing treatments for rb-positive abnormal cellular proliferation Sep. 18, 2018
  • Patent Title: Lactam kinase inhibitors Jan. 02, 2018
  • Patent Title: Lactam kinase inhibitors Aug. 29, 2017
  • Patent Title: Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation Aug. 01, 2017
  • Patent Title: Cdk inhibitors Nov. 22, 2016
  • Patent Title: Transient protection of normal cells during chemotherapy Nov. 08, 2016
  • Patent Title: Cdk inhibitors Nov. 01, 2016
  • Patent Title: Transient protection of normal cells during chemotherapy Oct. 11, 2016
  • Patent Title: Lactam kinase inhibitors Feb. 16, 2016
  • Patent Title: Cdk inhibitors Aug. 11, 2015
  • Patent Title: Cdk inhibitors Sep. 09, 2014
  • Patent Title: Cdk inhibitors Sep. 02, 2014
  • Patent Title: Cdk inhibitors Apr. 08, 2014
  • Patent Title: Cdk inhibitors Dec. 03, 2013
  • Patent Title: Cdk inhibitors Dec. 03, 2013
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of GTHX in WallStreetBets Daily Discussion

GTHX News

Recent insights relating to GTHX

CNBC Recommendations

Recent picks made for GTHX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in GTHX

GTHX Top Shareholders
Shareholder
Shares Held
GTHX Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

GTHX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view GTHX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top